GSK: agreement to acquire potential lupus treatment

(CercleFinance.com) - GSK announces that it has reached an agreement with Chimagen Biosciences (Chimagen) - an unlisted biotechnology company - to acquire CMG1A46, a clinical-stage T-cell engaging agent (TCE) for an initial amount of $300 million.


GSK plans to develop and commercialize CMG1A46 with a focus on B-cell-mediated autoimmune diseases such as systemic lupus erythematosus (SLE) and lupus nephritis (LN), with the possibility of expansion into related autoimmune diseases.

' As a new therapeutic option, CMG1A46 offers exciting potential that we are pleased to bring to bear to address unmet needs in lupus and other related autoimmune conditions', said Tony Wood, GSK's Chief Scientific Officer.

GSK says CMG1A46 is currently in Phase I clinical trials for leukemia and lymphoma in the US and China. The company aims to launch a Phase I trial in lupus in 2025.

Under the terms of the agreement, GSK will pay $300 million upfront to acquire full worldwide rights to CMG1A46. In addition, Chimagen will be eligible for milestone payments for the development and commercialization of CMG1A46, totaling $550 million.

Copyright (c) 2024 CercleFinance.com. All rights reserved.